Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 390Carboplatin 344pembrolizumab 331Gemcitabine 331Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 287Bevacizumab 250Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 190fludarabine 178Oxaliplatin 178Pemetrexed 154Doxorubicin 152Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 128Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interventional × eritoran × Clear all
NCT00756912 2014-07-11

A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Eisai Inc.

Phase 1 Terminated
30 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡